The effect of 17-alpha-hydroxy-19-norprogesterone caproate (SH582) on benign prostatic hypertrophy

Br J Surg. 1971 Sep;58(9):648-52. doi: 10.1002/bjs.1800580904.
No abstract available

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Acid Phosphatase / blood
  • Aged
  • Clinical Trials as Topic
  • Drug Hypersensitivity
  • Humans
  • Injections, Intramuscular
  • Male
  • Middle Aged
  • Organ Size
  • Placebos
  • Pregnanes / adverse effects
  • Pregnanes / therapeutic use*
  • Progestins / adverse effects
  • Progestins / therapeutic use
  • Prostate / diagnostic imaging
  • Prostatic Hyperplasia / drug therapy*
  • Pyuria / complications
  • Thyroid Gland / drug effects
  • Urinary Catheterization
  • Urography

Substances

  • Placebos
  • Pregnanes
  • Progestins
  • Acid Phosphatase